Anti-tuberculosis Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Global Anti-tuberculosis Therapeutics Market is segmented by Drug Class (Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Other Drug Classes), End User (Hospitals and Clinics, Government Agencies, Non-Profit Organizations, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the value (in USD million) for the above segments.

Anti-tuberculosis Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Anti-tuberculosis Therapeutics Industry Overview

The anti-tuberculosis therapeutics market is highly consolidated, with very few companies holding a substantial market share. With the rising focus of the healthcare sector on the development of novel drugs and the growing investment in research and development, more small to mid-sized companies are estimated to enter the market in the coming future. Some of the companies in the market are Lupin, Macleods Pharmaceuticals Ltd, Otsuka Pharmaceutical Co. Ltd, and Johnson and Johnson holds the largest market share.

Anti-tuberculosis Therapeutics Market Leaders

  1. Macleods Pharmaceuticals Ltd

  2. Otsuka Pharmaceutical Co. Ltd

  3. Johnson and Johnson

  4. Sequella, Inc.

  5. Lupin Limited

  6. *Disclaimer: Major Players sorted in no particular order
Anti-Tuberculosis Drugs Market Concentration

Anti-tuberculosis Therapeutics Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?